Compare Baidu Inc (BIDU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Baidu Inc trades at $112.75 (market cap $36.80B), while State Street SPDR S&P Biotech ETF trades at $154.89. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | XBI | |
|---|---|---|
Market Cap | $36.80B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $162.52 | $164.28 |
52-Week Low | $85.86 | $85.16 |
Enterprise Value | $33.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $113.39, down 3.52% amid bearish technical signals and mixed fundamentals. The stock faces pressure from declining revenue and net income margins, though it maintains strong analyst support with a $161 consensus price target. Recent news highlights AI optimism from Kunlunxin's potential $50 billion Hong Kong IPO, while cash flow trends show significant investing outflows. Technical indicators show bearish moving averages with neutral oscillators, trading near key support at $112.
Baidu presents a high-risk opportunity with Wall Street maintaining bullish ratings despite recent earnings volatility. The AI pivot and potential chip unit IPO offer growth catalysts, but declining profitability and negative cash flows pose substantial risks. Investors should weigh strong balance sheet strength against execution challenges in China's competitive tech landscape.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
